Scarica l'app Stockscreener
0.00
100.00%
-104.91
Precedente Chiudi:
$104.91
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$20.03B
Reddito:
$3.25B
Utile/perdita netta:
$-207.95M
Rapporto P/E:
0.00
EPS:
-1.1046
Flusso di cassa netto:
$356.78M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$104.98
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, IQV, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
0.00 | 20.03B | 3.25B | -207.95M | 356.78M | -1.1046 |
TMO
Thermo Fisher Scientific Inc
|
576.41 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.05 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
569.54 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
IQV
Iqvia Holdings Inc
|
242.94 | 35.59B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
140.54 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Exact Sciences stock trades steady as colorectal screening momentum meets earnings pressure - Ad-hoc-news.de
Exact Sciences stock advances on evidence from latest results - Ad-hoc-news.de
Patient Sues Abbott Labs, Exact Sciences in Data Theft - BankInfoSecurity
Exact Sciences stock trades steadily as revenue grows and screening portfolio expands - Ad-hoc-news.de
At Home Cancer Testing Market Size & Growth Analysis, 2026-2035 - Market Business Insights
Abbott Laboratories and Exact Sciences Corp Under Investigation for Data Breach of Patient Records - Schubert Jonckheer & Kolbe
Abbott Labs Accused Of Lax Security Over Shinyhunters Hack - Law360
Exact Sciences stock trades steady as revenue growth and screening demand support valuation - Ad-hoc-news.de
Exact Sciences stock trades near recent highs as screening demand supports revenue growth - Ad-hoc-news.de
Exact Sciences stock holds as investors await fresh numbers - AD HOC NEWS
Exact Sciences stock trades steadily as screening growth offsets guidance reset - Ad-hoc-news.de
Exact Sciences stock trades around recent range as screening revenue grows and losses narrow - Ad-hoc-news.de
Exact Sciences stock trades steady as Cologuard growth supports 2025 outlook - Ad-hoc-news.de
Abbott investigates two separate cyber incidents, says no operations affected - Reuters
Abbott raises 2026 profit forecast on strength in diagnostics, medical devices - Reuters
Abbott statement on cyber incident in Cancer Diagnostics business - Abbott
If You Invested $1,000 in Exact Sciences Corp (EXAS) - Stock Titan
Exact Sciences builds out cancer diagnostics. Operations and Nasdaq listing shape the story - ad-hoc-news.de
Exact Sciences Corp background and business model - ad-hoc-news.de
Exact Sciences stock leans on its screening base. Investors watch the U.S. testing franchise. - Ad-hoc-news.de
Exact Sciences focuses on cancer screening and long-term growth - Ad-hoc-news.de
Exact Sciences outlines long term diagnostics growth as cancer screening demand expands - ad-hoc-news.de
The Cologuard testExact Sciences leans on at-home colon cancer screening - Ad-hoc-news.de
Exact Sciences focuses on cancer diagnostics as investors track its long term growth prospects - ad-hoc-news.de
Exact Sciences Corp outlines growth ambitions as cancer screening demand expands - ad-hoc-news.de
Exact Sciences holds steady as investors await a fresh catalyst - AD HOC NEWS
Exact Sciences focuses on cancer diagnostics as investors weigh long-term growth - Ad-hoc-news.de
Exact Sciences highlights cancer screening focus as diagnostics portfolio expands - AD HOC NEWS
List of 29 Acquisitions by Abbott (Jul 2026) - Tracxn
Oncotype DX Breast Recurrence Score from Exact SciencesHow one test shapes US cancer care - AD HOC NEWS
Exact Sciences with steady analyst picture, shares trade on NASDAQ - Ad Hoc News
Exact Sciences opens the week with a clear earnings calendar, shares on NASDAQ in focus - ad-hoc-news.de
Cologuard from Exact Sciences Corp.multi-target stool DNA test reshapes home screening - Ad-hoc-news.de
Exact Sciences background and strategy, shares on NASDAQ in a diagnostics peer view - AD HOC NEWS
Exact Sciences consensus stays constructive, analysts see upside for the shares - AD HOC NEWS
Labcorp rolls out colorectal cancer screening test nationwide - MedTech Dive
Exact Sciences analyst focus on estimates, shares under Wall Street scrutiny - AD HOC NEWS
Align Technology Announces Board Leadership Transition: Kevin Conroy Named Chairman, Succeeding C. Raymond Larkin, Jr. in July 2026 - Minichart
Exact Sciences Corp (EXAS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exact Sciences StockAnalyst consensus and valuation snapshot - AD HOC NEWS
Why Cologuard from Exact Sciences is quietly changing at-home cancer screening - AD HOC NEWS
Align Taps Growth Architect Kevin Conroy as Chairman for Next Innovation Era - BriefGlance
Exact Sciences Corp (EXAS) Institutional Confidence - TradingKey
Exact Sciences Corp (EXAS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exact Sciences Corp (EXAS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exact Sciences Corp (EXAS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exact Sciences Corp (EXAS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exact Sciences Corp (EXAS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exact Sciences Corp (EXAS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exact Sciences Corp. Stock (US30063P1057): shares in focus amid quiet newsflow - AD HOC NEWS
Exact Sciences Corp. Stock (US30063P1057): Technical picture in focus after recent volatility - AD HOC NEWS
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
2.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):